GRAL · GRAIL, Inc.
$77.43
-0.17% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-7.9
Dividend yield
—
Beta
3.25
Avg volume
1M
Employees
1K
Daily Change %
-0.17%
5 Days Change
-3.56%
10 Days Change
-2.38%
30 Days Change
2.65%
60 Days Change
7.61%
Month to Day Change
-2.90%
Year to Day Change
-9.48%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GRAL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
UBS
Buy$105
+35.4% vs priceGoldman Sachs
Neutral$60.00
-22.6% vs priceMorgan Stanley
Equal-Weight$60.00
-22.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | UBS | Initiates | Buy | $0.00 → $105 |
| 2026-07-15 | Mizuho | Maintains | Neutral | $58.00 → $65.00 |
| 2026-06-05 | Goldman Sachs | Initiates | Neutral | $0.00 → $60.00 |
| 2026-05-06 | TD Cowen | Maintains | Buy | $65.00 → $69.00 |
| 2026-05-06 | Piper Sandler | Maintains | Neutral | $54.00 → $56.00 |
| 2026-04-10 | Mizuho | Initiates | Neutral | $0.00 → $58.00 |
| 2026-04-10 | Piper Sandler | Initiates | Neutral | $0.00 → $54.00 |
| 2026-03-30 | Guggenheim | Maintains | Buy | $130 → $75.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 52 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.6% above the 50-day MA ($73.29).
- Price vs 200-day MA: Trading 6.1% above the 200-day MA ($73.00).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.54) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($38.04) and high ($116.06).
GRAL Price Chart
Loading chart for GRAL…
Fundamentals
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
More in Diagnostics & Research
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.